This brief guide takes current clinical trial protocols to
task and replaces them with a contemporary framework for improving
next-generation antidepressants and their underlying science. Innovative models
are based on a nuanced, neurologically-informed understanding of drug
mechanisms and the component cognitive, mood, and behavioral aspects of
depression. The book reconceptualizes not only the clinical trial process but
the clinical concept of depression itself as essential to bringing
pharmaceutical research and development up to date, boosting efficiency and
effectiveness, finding new molecules, and reducing waste. Case studies and a
review of salient depression scales illustrate the potential benefits of such
wide-scale change. 

Included in the coverage: 

Why
now the need for a new clinical trials model for antidepressants?

• Aims
  and basic requirements of clinical trials: conventional and
  component-specific models.


• Methods
  for measuring the components and the profile of drug actions: the
  multivantaged approach.


• Achieving
  the ideal clinical trial: an example of the merged componential and
  established models.


• Prediction
  and shortening the clinical trial.


• The
  video clinical trial. 

Clinical Trials of
Antidepressants will interest a varied audience, including clinical
investigators, academic and pharmaceutical company scientists, clinical trial
organizations, psychiatrists, outpatient physicians, psychotherapists, clinical
psychologists, psychology graduate students, medical students, and government
agencies such as the FDA.